In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BlueRock Therapeutics

https://bluerocktx.com

Latest From BlueRock Therapeutics

Finance Watch: Billions In And Billions Out In Venture Capital Fundraising

Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.

Financing StartUps and SMEs

Bayer Boosts Gene Therapy Presence With AskBio Buy

After buying BlueRock Therapeutics outright last year, the Leverkusen-headquartered group has put down $2bn up front to acquire another cell and gene therapy specialist in Asklepios BioPharmaceutical.

M & A Gene Therapy

Moving Cell And Gene Therapies Into Chronic Conditions Depends On Durability, Safety

Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.

Gene Therapy Regenerative Medicine

Bayer To Settle Monsanto Litigation, Remains Prepared To Invest For Growth

The health care and crop science conglomerate will pay up to $10.9bn to resolve most Roundup claims, but still has capital to do bolt-on deals like last year’s BlueRock cell therapy buy.

Legal Issues Commercial
See All

Company Information

UsernamePublicRestriction

Register